PX1 Research has introduced a new line of US-manufactured sublingual peptide strips designed for needle-free research applications, featuring formulations for Retatrutide, Tirzepatide, and BPC-157. This launch marks a significant shift in how academic and institutional researchers can access peptide compounds, moving away from traditional injectable formats toward a non-invasive oral delivery method produced under domestic quality control standards.
The strips are manufactured in the United States under current Good Manufacturing Practice (cGMP) protocols, ensuring rigorous quality control throughout the production process. Each batch undergoes High-Performance Liquid Chromatography (HPLC) purity verification, with results confirming 99% or greater purity across all formulations. Researchers receive a Certificate of Analysis with each product, providing documented evidence of the batch composition before use. This emphasis on domestic manufacturing addresses the growing need for supply chain transparency in research environments, where documentation trails tracing production conditions are often required for institutional projects.
Among the available formulations, dissolving Retatrutide strips have drawn particular attention given the compound's role in ongoing metabolic and weight regulation research. The lineup also includes Tirzepatide, associated with glucose regulation studies, and BPC-157, which is being explored for tissue repair applications. The sublingual delivery format allows the strip to dissolve under the tongue, enabling absorption without the use of needles or syringes. This is especially valuable for research protocols that require non-invasive administration methods, whether due to study design specifications, institutional review considerations, or participant-facing requirements.
The full product line is accessible through [PX1 Research](https://px1research.com), with specific information on [dissolving Retatrutide strips](https://px1research.com/product/dissolving-retatrutide-strips/) available directly on the product page.
PX1 Research has positioned these sublingual peptide strips specifically for academic and institutional research contexts. The products are not intended for clinical, therapeutic, or human consumption use. Instead, they cater to researchers who need compounds delivered in a format compatible with non-invasive study designs, where traditional needle-based administration could introduce procedural variables or ethical complications.
The inclusion of BPC-157 alongside GLP-1 receptor agonist-class compounds like Retatrutide and Tirzepatide indicates the line is designed to serve a range of research disciplines. Each compound presents distinct molecular properties, and the sublingual strip format has been adapted to accommodate the specific stability and absorption characteristics relevant to each formulation.
PX1 Research is a US-based supplier of research-grade peptide formulations manufactured under cGMP standards. The company provides sublingual peptide strips and related compounds, each accompanied by HPLC purity verification and a Certificate of Analysis, for use in academic and institutional research settings. This launch underscores a broader trend toward more accessible and transparent research tools, potentially streamlining the workflow for investigators while aligning with ethical considerations in study design.
